Zoetis Company Profile (NYSE:ZTS)

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Zoetis announced a quarterly dividend on Friday, May 12th. Investors of record on Thursday, June 15th will be given a dividend of $0.105 per share on Friday, September 1st. This represents a $0.42 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend is Tuesday, June 13th. View Zoetis' Dividend History.

Zoetis Inc. (NYSE:ZTS) released its quarterly earnings results on Thursday, May, 4th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.05. The business had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.20 billion. Zoetis had a return on equity of 65.35% and a net margin of 17.25%. Zoetis's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the company posted $0.48 EPS. View Zoetis' Earnings History.

Zoetis is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Zoetis.

Zoetis issued an update on its FY17 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of $2.26-2.36 for the period, compared to the Thomson Reuters consensus estimate of $2.32. The company issued revenue guidance of $5.10-5.225 billion, compared to the consensus revenue estimate of $5.17 billion.

18 analysts have issued 12 month price objectives for Zoetis' shares. Their predictions range from $35.00 to $77.00. On average, they expect Zoetis' stock price to reach $61.94 in the next twelve months. View Analyst Ratings for Zoetis.

Here are some recent quotes from research analysts about Zoetis stock:

• 1. According to Zacks Investment Research, "Zoetis’ growth in revenues is being driven by sales of companion animal products such as Simparica, Apoquel and Cytopoint while the livestock portfolio was driven by growth in swine, cattle and fish across the international markets. Zoetis’ expects to see stronger growth from its companion animal portfolio in 2017 driven by Apoquel and Cytopoint, further penetration of Simparica, and ongoing uptake of new vaccines. Favorable market conditions contributed to swine performance in China as well as cattle product sales in Brazil. Moreover, the company undertook operational efficiency initiatives that are expected to generate cost savings of more than $300 million by the end of 2017. Shares of Zoetis have outperformed the industry in 2017 so far. However, disease outbreak among animals is a material cause of concern for Zoetis’ livestock products." (6/20/2017)
• 2. Guggenheim analysts commented, "We are raising our PT for ZTS shares after a 4Q beat and a lower than expected FX headwind for '17. The increase in our PT is driven by multiple expansion. We arrive at our new PT by using a DCF analysis. ZTS's solid execution this quarter increases our confidence that it can exceed consensus expectations for '17+ and sustain its 21x forward P/E multiple. Upward earnings revisions could come from margin expansion, M&A, and launches. Therefore, the sell-off today, which we think is motivated by profit taking, is overdone, in our view. We believe the weakness (ZTS down 3% vs. S&P down 0.14%) presents a good buying opportunity for the stock." (2/16/2017)

Some companies that are related to Zoetis include Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Stryker Corporation (SYK), Shire PLC (SHPG), Aetna (AET), Anthem (ANTM), Fresenius SE (FSNUY), Becton, Dickinson and Company (BDX), Takeda Pharmaceutical (TKPYY), Express Scripts Holding Company (ESRX), Boston Scientific Corporation (BSX), McKesson Corporation (MCK), Intuitive Surgical (ISRG), Humana (HUM), Baxter International (BAX), Vertex Pharmaceuticals Incorporated (VRTX), Teva Pharmaceutical Industries Limited (TEVA) and HCA Holdings (HCA).

Zoetis' management team includes the folowing people:

• Juan Ramon Alaix, Chief Executive Officer, Director
• Glenn David, Chief Financial Officer, Executive Vice President
• Roxanne Lagano, Chief Human Resource Officer, Executive Vice President
• Andrew Fenton, Executive Vice President, Chief Information Officer
• Heidi C. Chen, Executive Vice President, General Counsel, Corporate Secretary
• Alejandro Bernal, Executive Vice President, Group President - Strategy, Commercial and Business Development
• Catherine A. Knupp, Executive Vice President, President - Research and Development
• Clinton A. Lewis Jr., Executive Vice President, President - International Operations
• Kristin C. Peck, Executive Vice President, President - U.S. Operations
• Roman Trawicki, Executive Vice President, President of Global Manufacturing and Supply

Zoetis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.33%), Vanguard Group Inc. (6.66%), State Street Corp (4.33%), State Farm Mutual Automobile Insurance Co. (3.89%), Morgan Stanley (2.97%) and Independent Franchise Partners LLP (2.28%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck, Michael B Mccallister, Pershing Square Capital Manage and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.

Zoetis' stock was sold by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Principal Financial Group Inc., Marshall Wace LLP, Janus Capital Management LLC, Winslow Capital Management LLC, Alliancebernstein L.P., IronBridge Capital Management LP and Point72 Asset Management L.P.. Company insiders that have sold Zoetis stock in the last year include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck and Roxanne Lagano. View Insider Buying and Selling for Zoetis.

Zoetis' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Marshall Wace North America L.P., Waddell & Reed Financial Inc., California Public Employees Retirement System, State Street Corp, Prudential Financial Inc. and MARSHALL WACE ASIA Ltd. View Insider Buying and Selling for Zoetis.

Shares of Zoetis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Zoetis stock can currently be purchased for approximately $62.78.